Bard Announces Endologix Agreement for AAA Device.MURRAY HILL Murray Hill may refer to one of the following places:
C. R. Bard C. R. Bard, Inc. (NYSE: BCR) is one of the large S&P 500 companies of the United States, a surgical specialties and hospital medical device manufacturer in Murray Hill, New Jersey. It is named after its founder, who sold the company within only a few years of its founding. , Inc. (NYSE-BCR) today announced that is has entered into an exclusive agreement with Endologix, Inc., a California-based company that has developed an endoluminal graft (ELG ELG Early Learning Goals (education) ELG Export-Led Growth ELG Endoluminal Graft ELG Effluent Limitation Guideline ELG European Liaison Group ELG Executive Level Group ELG Engineering Log Generator ) used for the minimally invasive treatment of abdominal aortic aneurysms abdominal aortic aneurysm A focal aortic dilation of ≥ 50% ↑ in diameter, accompanied by distension and weakened aortic wall Epidemiology Incidence is rising 12/105–1951; 36/105 . The agreement gives Bard exclusive distribution rights to the Endologix ELG in Europe and Australia. The device was CE marked in Europe in May and registered for sale in Australia in June of this year. Endologix has initiated clinical studies in Japan to obtain marketing approval from the Ministry of Health and also plans to start their U.S. Phase I IDE clinical study in September. In addition to distribution rights, Bard has an exclusive and irrevocable option to acquire all of the capital stock of Endologix, Inc. before the end of the year 2000 at a pre-set price. Financial terms of the agreement were not disclosed. William H. Longfield, Bard's chairman and chief executive officer, said, "This agreement represents a significant step toward Bard's objective of obtaining market leadership in products used to treat peripheral vascular disease Peripheral Vascular Disease Definition Peripheral vascular disease is a narrowing of blood vessels that restricts blood flow. It mostly occurs in the legs, but is sometimes seen in the arms. . Early clinical results using the Endologix ELG device are very encouraging, especially with respect to endoleak rates and ease of delivery." Longfield concluded, "The addition of the Endologix ELG device expands Bard's already comprehensive line of technologically advanced vascular graft and stent products." The Endologix ELG is a fully supported one-piece abdominal aortic aortic pertaining to or emanating from the aorta. See also aortic arch. aortic aneurysm occurs most often in dogs, where it is caused by Spirocerca lupi larvae, turkeys and primates, causing dyspnea, cyanosis and coughing. device that was developed by prominent endovascular surgeons at the Arizona Heart Institute. Approximately 190,000 people are diagnosed each year with abdominal aortic aneurysms, which is a weakening of the wall of the aorta. Abdominal aortic aneurysms are the 13th leading cause of death in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. . Analysts estimate that the global market for ELGs to treat abdominal aortic aneurysms could reach $500 million by the year 2003. C. R. Bard, Inc., headquartered in Murray Hill, NJ, is a leading multinational developer, manufacturer and marketer of health care products. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion